Clinical Trial Update: Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2 [Phase 2]

View source ↗

Summary

Phase 2 trial update reporting safety and efficacy results for ABX-EGF in patients with advanced renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• ABX-EGF (panitumumab)

Snippet

Sponsor: Amgen | Conditions: Advanced Renal Cell Carcinoma | Phase 2 | Status: COMPLETED